InspireMD (NYSE:NSPR) Coverage Initiated at StockNews.com

Equities researchers at StockNews.com began coverage on shares of InspireMD (NYSE:NSPR) in a research note issued to investors on Monday. The brokerage set a “sell” rating on the stock.

InspireMD Stock Performance

Shares of NYSE:NSPR opened at $2.28 on Monday. The stock’s 50-day simple moving average is $2.54 and its two-hundred day simple moving average is $2.77. The stock has a market capitalization of $53.48 million, a price-to-earnings ratio of -2.11 and a beta of 0.84. InspireMD has a 52-week low of $0.96 and a 52-week high of $3.85.

InspireMD (NYSE:NSPR) last released its quarterly earnings results on Wednesday, March 6th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.04. The business had revenue of $1.76 million during the quarter, compared to the consensus estimate of $1.65 million. InspireMD had a negative return on equity of 55.71% and a negative net margin of 320.97%. During the same period in the previous year, the company posted ($0.60) EPS. As a group, equities analysts forecast that InspireMD will post -0.61 earnings per share for the current fiscal year.

Institutional Investors Weigh In On InspireMD

A number of large investors have recently made changes to their positions in NSPR. Renaissance Technologies LLC purchased a new position in shares of InspireMD during the 2nd quarter valued at about $36,000. Marshall Wace LLP purchased a new position in shares of InspireMD during the 2nd quarter valued at about $4,670,000. Avestar Capital LLC purchased a new position in shares of InspireMD during the 3rd quarter valued at about $65,000. McKinley Carter Wealth Services Inc. purchased a new position in shares of InspireMD during the 4th quarter valued at about $28,000. Finally, Northern Trust Corp purchased a new position in shares of InspireMD during the 4th quarter valued at about $80,000. 44.78% of the stock is currently owned by institutional investors.

InspireMD Company Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Delivery System, a mesh-covered self-expanding carotid stent; SwitchGuard, a non-invasive transcarotid artery revascularization device; and NGuard EPS for treating acute stroke with tandem lesions.